Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Navelbine oral and Arimidex as neoadjuvant treatment in post-menopausal women with locally advanced breast carcinoma
2004-000962-11Phase 2Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Jan 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine and anastrozole in breast cancer, sponsored by Pierre Fabre Laboratories. Primary endpoint: Tumor down-staging by ultrasound. Started Jan 2005; status: completed.
02
Drugs
vinorelbineanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-000962-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000962-11.